pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO
ALX ONCOLOGY HOLDINGS
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
- Founded
- 2015
- Employees
- 2
- Programs
- 13
- Drugs
- 16
- Patents
- 0
ALX ONCOLOGY HOLDINGS projects
7 ClinicalTrials.gov programs sponsored by ALX ONCOLOGY HOLDINGS.
ALX ONCOLOGY HOLDINGS has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AT148009
ALX ONCOLOGY HOLDINGS INC
Breast Cancer
1 trial -
AZACITIDINE
ALX ONCOLOGY HOLDINGS INC
Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
1 trial -
Evorpacept (ALX148)
ALX ONCOLOGY HOLDINGS INC
Microsatellite Stable Metastatic Colorectal Cancer
1 trial -
Evorpacept (ALX148)
ALX ONCOLOGY HOLDINGS INC
Breast Cancer, Metastatic
1 trial -
Pembrolizumab
ALX ONCOLOGY HOLDINGS INC
Ovarian Cancer
1 trial -
Zanidatamab
ALX ONCOLOGY HOLDINGS INC
HER2-expressing Cancers
1 trial -
evorpacept
ALX ONCOLOGY HOLDINGS INC
Head and Neck Cancer
2 trials
Frequently asked questions
How many clinical projects does ALX ONCOLOGY HOLDINGS have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.